Switch theme
Sign up to access all valuation multiples
Navamedic ASA is a pharmaceutical company supplying hospitals and pharmacies with pharmaceutical and medical nutrition products. The company generates its revenue from the Nordic countries.
2002
42
LTM Revenue $54.4M
LTM EBITDA $3.8M
$47.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Navamedic has a last 12-month revenue (LTM) of $54.4M and a last 12-month EBITDA of $3.8M.
In the most recent fiscal year, Navamedic achieved revenue of $52.7M and an EBITDA of $4.8M.
Navamedic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Navamedic valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $54.4M | XXX | $52.7M | XXX | XXX | XXX |
| Gross Profit | $21.4M | XXX | $20.7M | XXX | XXX | XXX |
| Gross Margin | 39% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $3.8M | XXX | $4.8M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $2.3M | XXX | $3.2M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $0.1M | XXX | -$0.5M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $9.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 3, 2025, Navamedic's stock price is NOK 22 (or $2).
Navamedic has current market cap of NOK 390M (or $38.7M), and EV of NOK 478M (or $47.4M).
See Navamedic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $47.4M | $38.7M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 3, 2025, Navamedic has market cap of $38.7M and EV of $47.4M.
Navamedic's trades at 0.9x EV/Revenue multiple, and 9.8x EV/EBITDA.
Equity research analysts estimate Navamedic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Navamedic has a P/E ratio of 716.0x.
See valuation multiples for Navamedic and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $38.7M | XXX | $38.7M | XXX | XXX | XXX |
| EV (current) | $47.4M | XXX | $47.4M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 12.4x | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBIT | 20.2x | XXX | 15.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 716.0x | XXX | -71.2x | XXX | XXX | XXX |
| EV/FCF | 20.4x | XXX | 13.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNavamedic's last 12 month revenue growth is 12%
Navamedic's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.4M for the same period.
Navamedic's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Navamedic's rule of X is 38% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Navamedic and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 62% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Navamedic acquired XXX companies to date.
Last acquisition by Navamedic was XXXXXXXX, XXXXX XXXXX XXXXXX . Navamedic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Navamedic founded? | Navamedic was founded in 2002. |
| Where is Navamedic headquartered? | Navamedic is headquartered in Norway. |
| How many employees does Navamedic have? | As of today, Navamedic has 42 employees. |
| Is Navamedic publicy listed? | Yes, Navamedic is a public company listed on OSL. |
| What is the stock symbol of Navamedic? | Navamedic trades under NAVA ticker. |
| When did Navamedic go public? | Navamedic went public in 2006. |
| Who are competitors of Navamedic? | Similar companies to Navamedic include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Navamedic? | Navamedic's current market cap is $38.7M |
| What is the current revenue of Navamedic? | Navamedic's last 12 months revenue is $54.4M. |
| What is the current revenue growth of Navamedic? | Navamedic revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Navamedic? | Current revenue multiple of Navamedic is 0.9x. |
| Is Navamedic profitable? | Yes, Navamedic is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Navamedic? | Navamedic's last 12 months EBITDA is $3.8M. |
| What is Navamedic's EBITDA margin? | Navamedic's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Navamedic? | Current EBITDA multiple of Navamedic is 12.4x. |
| What is the current FCF of Navamedic? | Navamedic's last 12 months FCF is $2.3M. |
| What is Navamedic's FCF margin? | Navamedic's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Navamedic? | Current FCF multiple of Navamedic is 20.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
